Literature DB >> 29858234

Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven.

Hugo J A Adams1, Thomas C Kwee2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29858234     DOI: 10.1182/blood-2018-04-845438

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  1 in total

Review 1.  Moving things forward in Hodgkin lymphoma.

Authors:  Paul J Bröckelmann; Boris Böll
Journal:  F1000Res       Date:  2018-11-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.